<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IMR</journal-id>
<journal-id journal-id-type="hwp">spimr</journal-id>
<journal-title>Journal of International Medical Research</journal-title>
<issn pub-type="ppub">0300-0605</issn>
<issn pub-type="epub">1473-2300</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0300060513476436</article-id>
<article-id pub-id-type="publisher-id">10.1177_0300060513476436</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Reports</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of axon guidance factor semaphorin 6B in the invasion and metastasis of gastric cancer</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Ge</surname><given-names>Changqing</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476436">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Li</surname><given-names>Quanfu</given-names></name>
<xref ref-type="aff" rid="aff1-0300060513476436">1</xref>
<xref ref-type="corresp" rid="corresp1-0300060513476436"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Lipu</given-names></name>
<xref ref-type="aff" rid="aff2-0300060513476436">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Xu</surname><given-names>Xu</given-names></name>
<xref ref-type="aff" rid="aff3-0300060513476436">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0300060513476436"><label>1</label>National Hepatobiliary and Enteric Surgery Research Centre, Central South University, Changsha, Hunan, China</aff>
<aff id="aff2-0300060513476436"><label>2</label>Department of Surgery, First Hospital of Traditional Chinese Medicine, Baoding, Heibei, China</aff>
<aff id="aff3-0300060513476436"><label>3</label>Department of Surgery, Second Renming Hospital, Baoding, Heibei, China</aff>
<author-notes>
<corresp id="corresp1-0300060513476436">Dr Quanfu Li, National Hepatobiliary and Enteric Surgery Research Centre, Central South University, 141 Xiangya Road, Kaifu District, Changsha City, Hunan Province 410003, China. Email: <email>liquanfu1968@hotmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>41</volume>
<issue>2</issue>
<fpage>284</fpage>
<lpage>292</lpage>
<history>
<date date-type="received"><day>6</day><month>11</month><year>2012</year></date>
<date date-type="accepted"><day>19</day><month>11</month><year>2012</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec17-0300060513476436"><title>Objective</title>
<p>To investigate the role of semaphorin 6B in gastric cancer invasion and metastasis.</p>
</sec>
<sec id="sec18-0300060513476436"><title>Methods</title>
<p>Immunohistochemistry for semaphorin 6B was performed on gastric cancer tumour tissue samples in this retrospective study. Levels of semaphorin 6B protein and mRNA were determined in gastric cancer cell lines by Western blotting and quantitative reverse transcription–polymerase chain reaction, respectively. The human gastric cancer cell line SGC-7901 was transfected with small interfering RNA targeting semaphorin 6B; effects on cell adhesion, migration and invasion were determined by cell adhesion assay, transwell chamber migration assay and wound healing assay, respectively.</p>
</sec>
<sec id="sec19-0300060513476436"><title>Results</title>
<p>Tumour tissue samples from 220 patients were analysed. <italic>In vivo</italic>, semaphorin 6B immunopositivity correlated with tumour differentiation, lymph node metastasis and distant metastasis but not patient age, sex or tumour stage. Semaphorin 6B gene silencing significantly suppressed adhesion, migration and invasion of gastric cancer cells <italic>in vitro</italic>.</p>
</sec>
<sec id="sec20-0300060513476436"><title>Conclusions</title>
<p>Semaphorin 6B is related to tumour differentiation and metastasis <italic>in vivo</italic>, and tumour cell migration, adhesion and invasion <italic>in vitro</italic>. Semaphorin 6B may represent a reliable biomarker for diagnosis, evaluation and gene-targeted therapy of gastric cancer.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Cell adhesion</kwd>
<kwd>gene expression</kwd>
<kwd>invasiveness</kwd>
<kwd>metastasis</kwd>
<kwd>RNA interference</kwd>
<kwd>semaphorin</kwd>
<kwd>stomach neoplasm</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0300060513476436" sec-type="intro"><title>Introduction</title>
<p>Semaphorin 6B is a member of the semaphorin class of proteins; these are involved in axonal guidance and play vital roles in central nervous system development.<sup><xref ref-type="bibr" rid="bibr1-0300060513476436">1</xref><xref ref-type="bibr" rid="bibr2-0300060513476436"/><xref ref-type="bibr" rid="bibr3-0300060513476436"/>–<xref ref-type="bibr" rid="bibr4-0300060513476436">4</xref></sup> Semaphorin expression is closely related to tumour invasion and metastasis in several human cancers,<sup><xref ref-type="bibr" rid="bibr5-0300060513476436">5</xref><xref ref-type="bibr" rid="bibr6-0300060513476436"/><xref ref-type="bibr" rid="bibr7-0300060513476436"/><xref ref-type="bibr" rid="bibr8-0300060513476436"/><xref ref-type="bibr" rid="bibr9-0300060513476436"/>–<xref ref-type="bibr" rid="bibr10-0300060513476436">10</xref></sup> but the association between semaphorin 6B expression and pathological features of gastric cancer is still poorly understood. In addition, the function of semaphorin 6B in the tumorigenesis and development of gastric cancer remains unknown.</p>
<p>The objectives of this study were to determine the presence of semaphorin 6B in gastric cancer tissue and to investigate the associations of semaphorin 6B with tumour stage, differentiation and metastasis. In addition, a gastric tumour cell line with decreased semaphorin B levels was established by small interfering RNA (siRNA) technology, in order to explore the function of semaphorin 6B in gastric cancer.</p>
</sec>
<sec id="sec2-0300060513476436" sec-type="methods"><title>Patients and methods</title>
<sec id="sec3-0300060513476436"><title>Study population</title>
<p>Tumour tissue specimens were retrospectively collected from patients with primary gastric cancer undergoing treatment at the Department of Surgery, Xiangya Hospital, Central South University, Changsha City, China between January 2005 and April 2010. Patients who had received previous radiotherapy or neoadjuvant therapy were excluded from the study; there were no other specific inclusion or exclusion criteria. Tumours were staged according to the stomach cancer staging guidelines of the American Joint Committee on Cancer.<sup><xref ref-type="bibr" rid="bibr11-0300060513476436">11</xref></sup></p>
<p>All patients provided written informed consent for the use of tissue specimens, and the study was approved by the Institutional Review Board for Human Research, at the National Hepatobiliary and Enteric Surgery Research Centre of Central South University, Changsha, Hunan, China.</p>
</sec>
<sec id="sec4-0300060513476436"><title>Immunohistochemistry</title>
<p>Tissue samples were fixed in 10% formalin, embedded in paraffin wax and cut into 4 -µm thick sections. Immunohistochemical staining was performed using the avidin–biotin–peroxidase (ABC) method.<sup><xref ref-type="bibr" rid="bibr12-0300060513476436">12</xref>,<xref ref-type="bibr" rid="bibr13-0300060513476436">13</xref></sup> Briefly, after deparaffinizing in xylene and rehydrating in ethanol, sections were heated in citrate buffer (0.01 M, pH 6.5) at 120°C for 10 min, then incubated with mouse antihuman semaphorin 6B (1 : 500 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or mouse antihuman β-actin (1 : 200 dilution; Santa Cruz Biotechnology) overnight at 4–8°C. Sections were washed four times with 0.1 M phosphate buffered saline (PBS; pH 7.4), then incubated with biotinylated goat antimouse immunoglobulin G (1 : 200 dilution; Vector Laboratories, Burlingame, CA, USA) at room temperature for 90 min. Slides were washed three times with PBS and immunoreactive staining was visualized using 0.5 mg/ml 3,3′-diaminobenzidine tetrahydrochloride and 0.03% hydrogen peroxide. Bovine serum albumin was used in place of primary antibody, as a negative control.</p>
<p>Ten high-power fields (×200 magnification) including the centre of the tumour and the invasive front, were examined by light microscopy; 100 tumour cells per field were evaluated to determine the presence of the distinct brown staining of the nucleus. Semaphorin 6B immunoreactivity was determined according to the mean proportion of positive cells: negative (&lt;5% stained); or positive (≥5% stained).<sup><xref ref-type="bibr" rid="bibr14-0300060513476436">14</xref><xref ref-type="bibr" rid="bibr15-0300060513476436"/><xref ref-type="bibr" rid="bibr16-0300060513476436"/>–<xref ref-type="bibr" rid="bibr17-0300060513476436">17</xref></sup></p>
</sec>
<sec id="sec5-0300060513476436"><title>Cell lines</title>
<p>The human gastric cancer cell lines AGS, SNU1, SGC-7901 and HGEC were obtained from American Type Culture Collection (Manassas, VA, USA); MKN45 was obtained from Japanese Collection of Research Bioresources (Osaka, Japan). Cells were maintained under standard conditions in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS) and 100 µg/ml penicillin/streptomycin.</p>
</sec>
<sec id="sec6-0300060513476436"><title>Western blotting</title>
<p>Total protein was extracted from cell lines by lysis in 0.1 M PBS (pH 7.4) containing 0.5% sodium deoxycholate, 1% Triton™ X-100 and 0.1% sodium dodecyl sulphate (SDS). Protein was quantified using bicinchoninic acid assay (Pierce, Rockford, IL, USA), and 100 µg protein per sample was dissolved in sample buffer (0.6 ml 1M Tris-HCl [pH 8.8], 2 ml 10% SDS, 5 ml 50% glycerol, 0.5 ml 2-mercaptoethanol, 1 ml 1% bromophenol blue and 40.9 ml sterilized water), separated via 10% SDS–polyacrylamide gel electrophoresis, and transferred to polyvinylidene difluoride membranes (Millipore, Bedford, IN, USA). Membranes were blocked with 5% nonfat dry milk in 1 × Tris buffered saline (pH 7.6) containing 0.1% Tween 20 (TBST) for 1 h at room temperature, then incubated with mouse antihuman semaphorin 6B (1 : 200 dilution; Santa Cruz Biotechnology) or mouse antihuman β-actin (1 : 500 dilution; Santa Cruz Biotechnology) at 4–8°C overnight. Membranes were washed five times in TBST (4 min each wash) then incubated in horseradish peroxidise-conjugated goat antimouse antibody (1 : 1000 dilution; Amersham Life Science, Buckinghamshire, UK) for 1 h at room temperature. Membranes were washed five times in TBST and immunoreactive proteins were visualized using an enhanced chemiluminescence kit (Amersham Life Science).</p>
</sec>
<sec id="sec7-0300060513476436"><title>Real-time RT–PCR</title>
<p>Total RNA was extracted from cultured cells (5 × 10<sup>5</sup> cells/well) using the Trizol® isolation kit (Invitrogen, Austin, TX, USA) and reverse transcribed with AMV Reverse Transcriptase (HC) (Promega, Madison, WI, USA), according to the manufacturers’ instructions. Real-time quantitative polymerase chain reaction (PCR) was performed using SYBR® Select Master Mix and a 7900HT sequence detection system (both from Applied Biosystems, Foster City, CA, USA). Each reaction mixture contained 300 nM each primer (see below), 2.5 µl 2 × SYBR® Green master mix (Applied Biosystems), and 0.1 µg cDNA (in 1 µl), to a final volume of 5 µl. Primer sequences were: semaphorin 6B (SEMA6B), forward 5′-GCCATGCAGACCCCGCGAGC-3′ and reverse 5′-CCACGTGGCATGCATGTCAG-3′; glucose-6-phosphate dehydrogenase (G6PDH), forward 5′-TGGACCTGACCTACGGCAACAGATA-3′ and reverse 5′-GCCCTCATACTGGAAACCC-3′.<sup><xref ref-type="bibr" rid="bibr3-0300060513476436">3</xref>,<xref ref-type="bibr" rid="bibr18-0300060513476436">18</xref></sup> The cycling programme involved preliminary denaturation at 50°C for 2 min then 95°C for 10 min, followed by 40 cycles of denaturation at 95°C for 15 s, annealing 60°C for 60 s, elongation at 60°C for 60 s, and a final dissociation step at 95°C for 15 s. All reactions were performed in triplicate wells of a 384-well microtitre plate. PCR products were quantitated relative to G6PDH levels.</p>
</sec>
<sec id="sec8-0300060513476436"><title>Construction of siRNA plasmid expression vector</title>
<p>Double-stranded oligonucleotides with complementary sequences encoding short hairpin RNA (shRNA) were obtained from Genesil Biotechnology Company (Wuhan, Hubei, China). The complementary sequence comprised two reversed repeated sequences with nine inserted sequences (TTCAAGAGA, AAGAACTCT), with recognition sites for BamHI and HindIII on both sides to facilitate ligation to the pSilencer™ 2.1 plasmid (Invitrogen). The targeting site of the transcribed oligonucleotide siRNA was nucleotides 76–84 of SEMA6B (GenBank® no. NM-020241). The negative control was a transcribed siRNA sequence with no homology to any human gene sequence.</p>
<p>To confirm the sequence of the siRNA, ligation was performed according to the manufacturer’s instructions and the recombinant pSilencer™ plasmid was transformed into <italic>Escherichia coli</italic> DH5a cells. Ampicillin-resistant colonies were cultured on solid luria broth medium at 37°C overnight on a rocking bed, and the sequence of the inserted 76 bp siRNA was verified by electrophoresis of the recombinant semaphorin 6B siRNA plasmid.<sup><xref ref-type="bibr" rid="bibr19-0300060513476436">19</xref></sup></p>
<p>Next, SGC-7901 cells were seeded in six-well plates (1 × 10<sup>5</sup>/well in 100 µl) and transfected with 100 nM pSilencer™ plasmid, containing either semaphorin 6B siRNA or control siRNA when confluence reached 90%. Transfection was performed using X-tremeGene siRNA transfection reagent (Roche, Indianapolis, IN, USA), according to the manufacturer’s instructions. At 48 h after transfection, cells were passaged 1 : 10, then cultured for 14 days in DMEM containing 600 µg/ml G418. The resulting cell lines were designated SGC-7901/Silence<sup>+</sup> and SGC-7901/Silence<sup>–</sup>.</p>
</sec>
<sec id="sec9-0300060513476436"><title>Adhesion assay</title>
<p>Cells (SGC-7901/Silence<sup>+</sup>, SGC-7901/Silence<sup>–</sup> or SGC-7901) were seeded in 96-well plates (3 × 10<sup>4</sup> cells/well in 50 µl) that were either uncoated or coated with fibronectin or matrix agarose. Cells were allowed to settle for 5 min; nonadherent cells were removed by aspiration and adherent cells were fixed with 4% paraformaldehyde, for 10 min. Fixed cells were incubated with 0.04% (v/v) Coomassie brilliant blue G-250 (in 25% ethanol, 12% acetic acid in double-distilled water) at 22°C for 45 min, then washed three times with wash solution (10% ethanol, 5% acetic acid in double distilled water). Cell-bound stain was resolubilized by incubation with 1 M potassium acetate (100 µl/well) for 45 min at 22°C and detected by measuring optical density at 595 nm. The percentage of adherent cells was determined by comparison with wells from which cells were not aspirated before fixation (maximum total cells/well, 3 × 10<sup>4</sup>).</p>
</sec>
<sec id="sec10-0300060513476436"><title>Migration assay</title>
<p>A migration assay was performed using a transwell chamber system with 8-mm porous filters (24-well format; Millipore, Billerica, MA, USA), in which cellular components are grown without direct cell-to-cell contact. SGC-7901/Silence<sup>+</sup>, SGC-7901/Silence<sup>–</sup> and SGC-7901 cells were diluted to 1 × 10<sup>6</sup> cells/ml in DMEM containing 0.5% FBS, and 50 000 cells/well were seeded into the upper compartment. The lower compartment of the chamber was filled with 1 ml DMEM containing 50 mg/ml hyaluronic acid. The chambers were incubated at 37°C for 36 h then removed from the plate. Cells that had migrated to the upper surface of the membrane were removed with cotton swabs; filters were fixed in 95% ethanol for 30 min then washed twice in distilled water. Filters were stained with 0.2% crystal violet for 20 min, rinsed twice with distilled water and examined via light microscopy. Cells were counted in five low-power fields (×40 magnification) and the cell invasion score was expressed as a percentage of untreated control cells (parental SGC-7901) cells.</p>
</sec>
<sec id="sec11-0300060513476436"><title>Scratch wound closure assay</title>
<p>Cell migration was determined using a scratch wound closure assay.<sup><xref ref-type="bibr" rid="bibr20-0300060513476436">20</xref></sup> SGC-7901/Silence<sup>+</sup>, SGC-7901/Silence<sup>–</sup> and SGC-7901 cells (10<sup>5</sup> cells/well in 100 µl) were cultured in 48-well plates, and a portion of the cell monolayer was scraped away with a sterile disposable rubber policeman. The remaining cells were washed with DMEM and incubated for a further 24 h. Cell migration into the denuded area was quantified with a computer-assisted microscope (MIC00266; Zeiss, Aalen, Germany).</p>
</sec>
<sec id="sec12-0300060513476436"><title>Statistical analyses</title>
<p>Data were expressed as mean ± SEM and compared using one-way analysis of variance. Statistical analyses were performed with SPSS® software, version 18.0 (SPSS Inc., Chicago, IL, USA) for Windows®. A <italic>P</italic>-value&lt; 0.05 was considered statistically significant.</p>
</sec>
</sec>
<sec id="sec13-0300060513476436" sec-type="results"><title>Results</title>
<p>The study included tissue samples from 220 patients with primary gastric cancer (median age 59 years, range 36–76 years; 146 males/74 females). Semaphorin 6B immunopositivity was correlated with distant metastasis (<italic>P</italic> &lt; 0.001), lymph node metastasis (<italic>P</italic> = 0.011) and differentiation stage (<italic>P</italic> = 0.012). There was no correlation between semaphorin 6B immunopositivity and patient age, sex or tumour stage (<xref ref-type="table" rid="table1-0300060513476436">Table 1</xref>).
<table-wrap id="table1-0300060513476436" position="float"><label>Table 1.</label><caption><p>Correlations between semaphorin 6B immunopositivity and demographic and clinicopathological characteristics of patients with primary gastric cancer (<italic>n</italic> = 220).</p></caption>
<graphic alternate-form-of="table1-0300060513476436" xlink:href="10.1177_0300060513476436-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th rowspan="2">Parameter</th>
<th rowspan="2"><italic>n</italic></th>
<th colspan="2">Semaphorin 6B</th>
<th rowspan="2">Statistical significance<sup><xref ref-type="table-fn" rid="table-fn2-0300060513476436">a</xref></sup></th>
</tr>
<tr><th>Negative</th>
<th>Positive</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age, years</td>
<td>NS</td>
</tr>
<tr>
<td> &gt; 60</td>
<td>104</td>
<td>38</td>
<td>66</td>
</tr>
<tr>
<td> ≤ 60</td>
<td>116</td>
<td>44</td>
<td>72</td>
</tr>
<tr>
<td>Sex</td>
<td>NS</td>
</tr>
<tr>
<td> Male</td>
<td>146</td>
<td>49</td>
<td>97</td>
</tr>
<tr>
<td> Female</td>
<td>74</td>
<td>33</td>
<td>41</td>
</tr>
<tr>
<td>Tumour stage<sup><xref ref-type="bibr" rid="bibr11-0300060513476436">11</xref></sup></td>
<td>NS</td>
</tr>
<tr>
<td> T<sup><xref ref-type="bibr" rid="bibr1-0300060513476436">1</xref></sup></td>
<td>53</td>
<td>19</td>
<td>34</td>
</tr>
<tr>
<td> T<sup><xref ref-type="bibr" rid="bibr2-0300060513476436">2</xref></sup></td>
<td>50</td>
<td>18</td>
<td>32</td>
</tr>
<tr>
<td> T<sup><xref ref-type="bibr" rid="bibr3-0300060513476436">3</xref></sup></td>
<td>58</td>
<td>22</td>
<td>36</td>
</tr>
<tr>
<td> T<sup><xref ref-type="bibr" rid="bibr4-0300060513476436">4</xref></sup></td>
<td>59</td>
<td>23</td>
<td>36</td>
</tr>
<tr>
<td>Distant metastasis</td>
<td><italic>P</italic> &lt; 0.001</td>
</tr>
<tr>
<td> Absent</td>
<td>160</td>
<td>66</td>
<td>94</td>
</tr>
<tr>
<td> Present</td>
<td>60</td>
<td>16</td>
<td>44</td>
</tr>
<tr>
<td>Lymph node metastasis<sup><xref ref-type="bibr" rid="bibr11-0300060513476436">11</xref></sup></td>
<td><italic>P</italic> = 0.011</td>
</tr>
<tr>
<td> N<sup>0</sup></td>
<td>50</td>
<td>24</td>
<td>26</td>
</tr>
<tr>
<td> N<sup><xref ref-type="bibr" rid="bibr1-0300060513476436">1</xref></sup></td>
<td>44</td>
<td>21</td>
<td>23</td>
</tr>
<tr>
<td> N<sup><xref ref-type="bibr" rid="bibr2-0300060513476436">2</xref></sup></td>
<td>69</td>
<td>19</td>
<td>50</td>
</tr>
<tr>
<td> N<sup><xref ref-type="bibr" rid="bibr3-0300060513476436">3</xref></sup></td>
<td>57</td>
<td>18</td>
<td>39</td>
</tr>
<tr>
<td>Differentiation</td>
<td><italic>P</italic> = 0.012</td>
</tr>
<tr>
<td> High/moderate</td>
<td>108</td>
<td>43</td>
<td>65</td>
</tr>
<tr>
<td> Poor/none</td>
<td>112</td>
<td>62</td>
<td>50</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0300060513476436"><p>Data presented as <italic>n</italic> of patients.</p></fn>
<fn id="table-fn2-0300060513476436"><label>a</label><p>One-way analysis of variance.</p></fn>
<fn id="table-fn3-0300060513476436"><p>NS, not statistically significant (<italic>P</italic> ≥ 0.05).</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Levels of semaphorin 6B mRNA were significantly higher in SGC-7901 cells (4.76 ± 0.25) than in MKN45 (2.23 ± 0.21; <italic>P</italic> = 0.031), SNU1 (2.12 ± 0.12; <italic>P</italic> = 0.026), AGS (1.98 ± 0.09; <italic>P</italic> = 0.014) or HGEC cells (0.95 ± 0.14; <italic>P</italic> = 0.008). In addition, semaphorin 6B protein levels were visibly higher in SGC-7901 cells than in other cell lines studied (<xref ref-type="fig" rid="fig1-0300060513476436">Figure 1</xref>). As a result, SGC-7901 cells were selected for subsequent assays.
<fig id="fig1-0300060513476436" position="float"><label>Figure 1.</label><caption><p>Detection of semaphorin 6B protein in five human gastric carcinoma cell lines (HGEC, AGS, SNU1, MKN45 and SG-7901) by Western blotting. β-actin used as the protein loading control.</p></caption><graphic xlink:href="10.1177_0300060513476436-fig1.tif"/>
</fig></p>
<p>Transfection of SGC-7901 cells with semaphorin 6B siRNA significantly reduced semaphorin 6B protein levels, compared with those observed in parental SGC-7901 cells (<italic>P</italic> &lt; 0.001; <xref ref-type="table" rid="table2-0300060513476436">Table 2</xref>, <xref ref-type="fig" rid="fig2-0300060513476436">Figure 2</xref>), and significantly reduced adherence to fibronectin and matrix agarose compared with parental cells (<italic>P</italic> = 0.04 and <italic>P</italic> = 0.01, respectively; <xref ref-type="table" rid="table2-0300060513476436">Table 2</xref>). In addition, transwell cell migration and scratch closure migration were also significantly reduced by semaphorin 6B siRNA transfection (<italic>P</italic> &lt; 0.01 for both comparisons; <xref ref-type="table" rid="table2-0300060513476436">Table 2</xref>).
<fig id="fig2-0300060513476436" position="float"><label>Figure 2.</label><caption><p>Western blotting detection of semaphorin 6B protein in (A) the human gastric carcinoma cell line SGC-7901, SGC-7901 cells transfected with pSilencer™ 2.1 plasmid (Invitrogen, Austin, TX, USA) encoding (B) control small interfering RNA (siRNA) (SGC-7901/Silence<sup>–</sup>) and (C) siRNA targeting semaphorin 6B expression (SGC-7901/Silence<sup>+</sup>). β-actin used as the protein loading control.</p></caption><graphic xlink:href="10.1177_0300060513476436-fig2.tif"/>
</fig>
<table-wrap id="table2-0300060513476436" position="float"><label>Table 2.</label><caption><p>Semaphorin 6B protein levels, adhesion, migration and invasion in cells of the human gastric carcinoma cell line SGC-7901 transfected with pSilencer™ 2.1 plasmid (Invitrogen, Austin, TX, USA) encoding control small interfering RNA targeting semaphorin 6B expression (SGC-7901/Silence<sup>+</sup>) or control siRNA (SGC-7901/Silence<sup>–</sup>), and parental SGC-7901 cells.</p></caption>
<graphic alternate-form-of="table2-0300060513476436" xlink:href="10.1177_0300060513476436-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Parameter</th>
<th>SGC-7901</th>
<th>SGC-7901/Silence<sup>+</sup></th>
<th>SGC-7901/Silence<sup>−</sup></th>
</tr></thead>
<tbody align="left">
<tr>
<td>Semaphorin 6B protein<sup><xref ref-type="table-fn" rid="table-fn5-0300060513476436">a</xref></sup></td>
<td>1.46 ± 0.38</td>
<td>0.38 ± 0.18***</td>
<td>1.14 ± 0.42</td>
</tr>
<tr>
<td>Fibronectin adhesion, % of total cells</td>
<td>78.5 ± 6.0</td>
<td>43.2 ± 2.0<xref ref-type="table-fn" rid="table-fn6-0300060513476436">*</xref></td>
<td>74.8 ± 5.7</td>
</tr>
<tr>
<td>Matrix agarose adhesion, % of total cells</td>
<td>69.1 ± 5.5</td>
<td>40.9 ± 2.1<xref ref-type="table-fn" rid="table-fn6-0300060513476436">*</xref></td>
<td>67.8 ± 5.3</td>
</tr>
<tr>
<td>Migration, cells</td>
<td>413.2 ± 162.6</td>
<td>139.7 ± 84.5**</td>
<td>409.4 ± 183.8</td>
</tr>
<tr>
<td>Invasion, % of total cells</td>
<td>98.1 ± 10.6</td>
<td>46.4 ± 13.5**</td>
<td>96.7 ± 24.3</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-0300060513476436"><p>Data presented as mean ± SEM.</p></fn>
<fn id="table-fn5-0300060513476436"><label>a</label><p>Determined by Western blotting, relative to β actin.</p></fn>
<fn id="table-fn6-0300060513476436"><label>*</label><p><italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, and ***<italic>P</italic> &lt; 0.001 vs SGC-7901; one-way analysis of variance.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec14-0300060513476436" sec-type="discussion"><title>Discussion</title>
<p>Semaphorins are a group of axonal growth cone guidance proteins, with over 30 members identified in eight major subfamilies.<sup><xref ref-type="bibr" rid="bibr21-0300060513476436">21</xref><xref ref-type="bibr" rid="bibr22-0300060513476436"/>–<xref ref-type="bibr" rid="bibr23-0300060513476436">23</xref></sup> The semaphorin proteins share a similar structure, defined by a highly conserved cysteine-rich sema domain at the <sc>N</sc>-terminus.<sup><xref ref-type="bibr" rid="bibr24-0300060513476436">24</xref>,<xref ref-type="bibr" rid="bibr25-0300060513476436">25</xref></sup> Semaphorins were initially identified in the nervous system, with functions in axon guidance, inhibition of axonal branches and induction into the targeted region.<sup><xref ref-type="bibr" rid="bibr14-0300060513476436">14</xref>,<xref ref-type="bibr" rid="bibr26-0300060513476436">26</xref><xref ref-type="bibr" rid="bibr27-0300060513476436"/>–<xref ref-type="bibr" rid="bibr28-0300060513476436">28</xref></sup> Studies have indicated that some members of the semaphorin family are not restricted to the nervous system and have major roles in many other processes.<sup><xref ref-type="bibr" rid="bibr15-0300060513476436">15</xref>,<xref ref-type="bibr" rid="bibr29-0300060513476436">29</xref></sup> Semaphorins (including 3 A, 4D, 5 A, 5 C and 7 A) play important roles in tumorigenesis and tumour development by promoting angiogenesis and tumour cell migration.<sup><xref ref-type="bibr" rid="bibr12-0300060513476436">12</xref>,<xref ref-type="bibr" rid="bibr13-0300060513476436">13</xref>,<xref ref-type="bibr" rid="bibr16-0300060513476436">16</xref>,<xref ref-type="bibr" rid="bibr30-0300060513476436">30</xref><xref ref-type="bibr" rid="bibr31-0300060513476436"/><xref ref-type="bibr" rid="bibr32-0300060513476436"/><xref ref-type="bibr" rid="bibr33-0300060513476436"/><xref ref-type="bibr" rid="bibr34-0300060513476436"/>–<xref ref-type="bibr" rid="bibr35-0300060513476436">35</xref></sup> In contrast, semaphorin 3B and 3 F have been shown to have tumour inhibitory effects.<sup><xref ref-type="bibr" rid="bibr17-0300060513476436">17</xref>,<xref ref-type="bibr" rid="bibr36-0300060513476436">36</xref></sup> The presence of semaphorin 6B was correlated with tumour differentiation, lymph node metastasis and distant metastasis of gastric cancer in the present study, but unrelated to patient age, sex or tumour stage, suggesting that semaphorin 6B may play a role in tumorigenesis and development of gastric cancer.</p>
<p>Cancer invasion and metastasis are closely related to adhesion, migration and invasion of cancer cells.<sup><xref ref-type="bibr" rid="bibr37-0300060513476436">37</xref></sup> In the present study, inhibition of semaphorin 6B expression via RNA interference significantly inhibited the migration, adhesion and invasion abilities of SGC-7901 gastric cancer cells <italic>in vitro</italic>. These findings indicate that semaphorin 6B may promote gastric cancer invasion and metastasis by upregulation of extracellular matrix adhesion, migration and invasion, but the mechanism remains to be elucidated.</p>
<p>In conclusion, the presence of semaphorin 6B is closely related to tumour differentiation and metastasis <italic>in vivo</italic>, and to tumour cell migration, adhesion and invasion <italic>in vitro</italic>. Semaphorin 6B may represent a reliable biomarker for the clinical diagnosis, evaluation and gene-targeted therapy for gastric cancer.</p>
</sec>
</body>
<back>
<sec id="sec15-0300060513476436"><title>Declaration of conflicting interest</title>
<p>The authors had no conflicts of interest to declare in relation to this article.</p>
</sec>
<sec id="sec16-0300060513476436"><title>Funding</title>
<p>This study was supported by the Fundamental Research Fund for the Central Universities of Central South University, Changsha City, China.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0300060513476436"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>BP</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name></person-group>. <article-title>Semaphorin-mediated axonal guidance via Rho-related G proteins</article-title>. <source>Curr Opin Cell Biol</source> <year>2001</year>; <volume>13</volume>: <fpage>619</fpage>–<lpage>626</lpage>.</citation></ref>
<ref id="bibr2-0300060513476436"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Muratori</surname><given-names>C</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name></person-group>. <article-title>Semaphorin signals tweaking the tumor microenvironment</article-title>. <source>Adv Cancer Res</source> <year>2012</year>; <volume>114</volume>: <fpage>59</fpage>–<lpage>85</lpage>.</citation></ref>
<ref id="bibr3-0300060513476436"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Correa</surname><given-names>RG</given-names></name><name><surname>Sasahara</surname><given-names>RM</given-names></name><name><surname>Bengtson</surname><given-names>MH</given-names></name><etal/></person-group>. <article-title>Human semaphorin 6B [(<italic>HSA)SEMA6B</italic>], a novel human class 6 semaphorin gene: alternative splicing and all-<italic>trans</italic>-retinoic acid-dependent downregulation in glioblastoma cell lines</article-title>. <source>Genomics</source> <year>2001</year>; <volume>73</volume>: <fpage>343</fpage>–<lpage>348</lpage>.</citation></ref>
<ref id="bibr4-0300060513476436"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name><name><surname>Zhai</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Identification, characterization, and functional study of the two novel human members of the semaphorin gene family</article-title>. <source>J Biol Chem</source> <year>2002</year>; <volume>277</volume>: <fpage>35574</fpage>–<lpage>35585</lpage>.</citation></ref>
<ref id="bibr5-0300060513476436"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beuten</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>D</given-names></name><name><surname>Brand</surname><given-names>TC</given-names></name><etal/></person-group>. <article-title>Semaphorin 3B and 3F single nucleotide polymorphisms are associated with prostate cancer risk and poor prognosis</article-title>. <source>J Urol</source> <year>2009</year>; <volume>182</volume>: <fpage>1614</fpage>–<lpage>1620</lpage>.</citation></ref>
<ref id="bibr6-0300060513476436"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gabrovska</surname><given-names>PN</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Tiang</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Semaphorin–plexin signalling genes associated with human breast tumourigenesis</article-title>. <source>Gene</source> <year>2011</year>; <volume>489</volume>: <fpage>63</fpage>–<lpage>69</lpage>.</citation></ref>
<ref id="bibr7-0300060513476436"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Rosenbaugh</surname><given-names>EG</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Semaphorin 5A promotes angiogenesis by increasing endothelial cell proliferation, migration, and decreasing apoptosis</article-title>. <source>Microvasc Res</source> <year>2010</year>; <volume>79</volume>: <fpage>1</fpage>–<lpage>9</lpage>.</citation></ref>
<ref id="bibr8-0300060513476436"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>YH</given-names></name><name><surname>Binmadi</surname><given-names>NO</given-names></name><etal/></person-group>. <article-title>The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma</article-title>. <source>Exp Cell Res</source> <year>2012</year>; <volume>318</volume>: <fpage>1685</fpage>–<lpage>1698</lpage>.</citation></ref>
<ref id="bibr9-0300060513476436"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>G</given-names></name><name><surname>Shraga-Heled</surname><given-names>N</given-names></name><name><surname>Lange</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Semaphorins in cancer</article-title>. <source>Front Biosci</source> <year>2005</year>; <volume>10</volume>: <fpage>751</fpage>–<lpage>760</lpage>.</citation></ref>
<ref id="bibr10-0300060513476436"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trusolino</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group>. <article-title>Scatter-factor and semaphorin receptors: cell signalling for invasive growth</article-title>. <source>Nat Rev Cancer</source> <year>2002</year>; <volume>2</volume>: <fpage>289</fpage>–<lpage>300</lpage>.</citation></ref>
<ref id="bibr11-0300060513476436"><label>11</label><citation citation-type="book"><collab>American Joint Committee on Cancer</collab>. <article-title>Stomach Cancer</article-title>. <source><italic>In:</italic> AJCC Cancer Staging Manual</source>, <edition>7th ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2010</year>, pp. <fpage>117</fpage>–<lpage>121</lpage>.</citation></ref>
<ref id="bibr12-0300060513476436"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Woodhouse</surname><given-names>EC</given-names></name><name><surname>Fisher</surname><given-names>A</given-names></name><name><surname>Bandle</surname><given-names>RW</given-names></name></person-group>. <article-title><italic>Drosophila</italic> screening model for metastasis: Semaphorin 5c is required for <italic>l(2)gl</italic> cancer phenotype</article-title>. <source>Proc Natl Acad Sci USA</source> <year>2003</year>; <volume>100</volume>: <fpage>11463</fpage>–<lpage>11468</lpage>.</citation></ref>
<ref id="bibr13-0300060513476436"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>GA</given-names></name><name><surname>McClelland</surname><given-names>LA</given-names></name><name><surname>Fricke</surname><given-names>AF</given-names></name></person-group>. <article-title>Semaphorin 7a promotes spreading and dendricity in human melanocytes through <italic>β</italic>1-integrins</article-title>. <source>J Invest Dermatol</source> <year>2008</year>; <volume>128</volume>: <fpage>151</fpage>–<lpage>161</lpage>.</citation></ref>
<ref id="bibr14-0300060513476436"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieger</surname><given-names>J</given-names></name><name><surname>Wick</surname><given-names>W</given-names></name><name><surname>Weller</surname><given-names>M</given-names></name></person-group>. <article-title>Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins</article-title>. <source>Glia</source> <year>2003</year>; <volume>42</volume>: <fpage>379</fpage>–<lpage>389</lpage>.</citation></ref>
<ref id="bibr15-0300060513476436"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shirvan</surname><given-names>A</given-names></name><name><surname>Ziv</surname><given-names>I</given-names></name><name><surname>Fleminger</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Semaphorins as mediators of neuronal apoptosis</article-title>. <source>J Neurochem</source> <year>1999</year>; <volume>73</volume>: <fpage>961</fpage>–<lpage>971</lpage>.</citation></ref>
<ref id="bibr16-0300060513476436"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bielenberg</surname><given-names>DR</given-names></name><name><surname>Klagsbrun</surname><given-names>M</given-names></name></person-group>. <article-title>Targeting endothelial and tumor cells with semaphorins</article-title>. <source>Cancer Metastasis Rev</source> <year>2007</year>; <volume>26</volume>: <fpage>421</fpage>–<lpage>431</lpage>.</citation></ref>
<ref id="bibr17-0300060513476436"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nasarre</surname><given-names>P</given-names></name><name><surname>Constantin</surname><given-names>B</given-names></name><name><surname>Rouhaud</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading</article-title>. <source>Neoplasia</source> <year>2003</year>; <volume>5</volume>: <fpage>83</fpage>–<lpage>92</lpage>.</citation></ref>
<ref id="bibr18-0300060513476436"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Mabuchi</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Prognostic significance and different properties of survivin splicing variants in gastric cancer</article-title>. <source>Cancer Lett</source> <year>2004</year>; <volume>216</volume>: <fpage>147</fpage>–<lpage>155</lpage>.</citation></ref>
<ref id="bibr19-0300060513476436"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>In vitro inhibition of CSFV replication by multiple siRNA expression</article-title>. <source>Antiviral Res</source> <year>2011</year>; <volume>91</volume>: <fpage>209</fpage>–<lpage>216</lpage>.</citation></ref>
<ref id="bibr20-0300060513476436"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weis</surname><given-names>M</given-names></name><name><surname>Heeschen</surname><given-names>C</given-names></name><name><surname>Glassford</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Statins have biphasic effects on angiogenesis</article-title>. <source>Circulation</source> <year>2002</year>; <volume>105</volume>: <fpage>739</fpage>–<lpage>745</lpage>.</citation></ref>
<ref id="bibr21-0300060513476436"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yazdani</surname><given-names>U</given-names></name><name><surname>Terman</surname><given-names>JR</given-names></name></person-group>. <article-title>The semaphorins</article-title>. <source>Genome Biol</source> <year>2006</year>; <volume>7</volume>: <fpage>211</fpage>–<lpage>211</lpage>.</citation></ref>
<ref id="bibr22-0300060513476436"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casazza</surname><given-names>A</given-names></name><name><surname>Fazzari</surname><given-names>P</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name></person-group>. <article-title>Semaphorin signals in cell adhesion and cell migration: functional role and molecular mechanisms</article-title>. <source>Adv Exp Med Biol</source> <year>2007</year>; <volume>600</volume>: <fpage>90</fpage>–<lpage>108</lpage>.</citation></ref>
<ref id="bibr23-0300060513476436"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shifman</surname><given-names>MI</given-names></name><name><surname>Selzer</surname><given-names>ME</given-names></name></person-group>. <article-title>Semaphorins and their receptors in lamprey CNS: cloning, phylogenetic analysis, and developmental changes during metamorphosis</article-title>. <source>J Compar Neurol</source> <year>2006</year>; <volume>497</volume>: <fpage>115</fpage>–<lpage>132</lpage>.</citation></ref>
<ref id="bibr24-0300060513476436"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Raper</surname><given-names>JA</given-names></name></person-group>. <article-title>Semaphorins and their receptors in vertebrates and invertebrates</article-title>. <source>Curr Opin Neurobiol</source> <year>2000</year>; <volume>10</volume>: <fpage>88</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr25-0300060513476436"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruger</surname><given-names>RP</given-names></name><name><surname>Aurandt</surname><given-names>J</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group>. <article-title>Semaphorins command cells to move</article-title>. <source>Nat Rev Mol Cell Biol</source> <year>2005</year>; <volume>6</volume>: <fpage>789</fpage>–<lpage>800</lpage>.</citation></ref>
<ref id="bibr26-0300060513476436"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RI</given-names></name><name><surname>Rottkamp</surname><given-names>DM</given-names></name><name><surname>Maric</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>A role for semaphorins and neuropilins in oligodendrocyte guidance</article-title>. <source>J Neurochem</source> <year>2003</year>; <volume>85</volume>: <fpage>1262</fpage>–<lpage>1278</lpage>.</citation></ref>
<ref id="bibr27-0300060513476436"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takegahara</surname><given-names>N</given-names></name><name><surname>Kumanogoh</surname><given-names>A</given-names></name></person-group>. <article-title>Involvement of semaphorins and their receptors in neurological diseases</article-title>. <source>Clin Exp Neuroimmunol</source> <year>2010</year>; <volume>1</volume>: <fpage>33</fpage>–<lpage>45</lpage>.</citation></ref>
<ref id="bibr28-0300060513476436"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>F</given-names></name><name><surname>Kalb</surname><given-names>RG</given-names></name><name><surname>Strittmatter</surname><given-names>SM</given-names></name></person-group>. <article-title>Molecular basis of semaphorin-mediated axon guidance</article-title>. <source>J Neurobiol</source> <year>2000</year>; <volume>44</volume>: <fpage>219</fpage>–<lpage>229</lpage>.</citation></ref>
<ref id="bibr29-0300060513476436"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>L</given-names></name><name><surname>Koncina</surname><given-names>E</given-names></name><name><surname>Satkauskas</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The many faces of semaphorins: from development to pathology</article-title>. <source>Cell Mol Life Sci</source> <year>2009</year>; <volume>66</volume>: <fpage>649</fpage>–<lpage>666</lpage>.</citation></ref>
<ref id="bibr30-0300060513476436"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Nawabi-Ghasimi</surname><given-names>F</given-names></name><name><surname>Basile</surname><given-names>JR</given-names></name></person-group>. <article-title>Semaphorins in vascular development and head and neck squamous cell carcinoma-induced angiogenesis</article-title>. <source>Oral Oncol</source> <year>2008</year>; <volume>44</volume>: <fpage>523</fpage>–<lpage>531</lpage>.</citation></ref>
<ref id="bibr31-0300060513476436"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Neufeld</surname><given-names>G</given-names></name><name><surname>Kessler</surname><given-names>O</given-names></name></person-group>. <article-title>The semaphorins: versatile regulators of tumour progression and tumour angiogenesis</article-title>. <source>Nat Rev Cancer</source> <year>2008</year>; <volume>8</volume>: <fpage>632</fpage>–<lpage>645</lpage>.</citation></ref>
<ref id="bibr32-0300060513476436"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chédotal</surname><given-names>A</given-names></name><name><surname>Kerjan</surname><given-names>G</given-names></name><name><surname>Moreau-Fauvarque</surname><given-names>C</given-names></name></person-group>. <article-title>The brain within the tumor: new roles for axon guidance molecules in cancers</article-title>. <source>Cell Death Differ</source> <year>2005</year>; <volume>12</volume>: <fpage>1044</fpage>–<lpage>1056</lpage>.</citation></ref>
<ref id="bibr33-0300060513476436"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadanandam</surname><given-names>A</given-names></name><name><surname>Varney</surname><given-names>ML</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>High gene expression of semaphorin 5A in pancreatic cancer is associated with tumor growth, invasion and metastasis</article-title>. <source>Int J Cancer</source> <year>2010</year>; <volume>127</volume>: <fpage>1373</fpage>–<lpage>1383</lpage>.</citation></ref>
<ref id="bibr34-0300060513476436"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>MW</given-names></name><name><surname>Giese</surname><given-names>NA</given-names></name><name><surname>Swiercz</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Association of axon guidance factor semaphorin 3A with poor outcome in pancreatic cancer</article-title>. <source>Int J Cancer</source> <year>2007</year>; <volume>121</volume>: <fpage>2421</fpage>–<lpage>2433</lpage>.</citation></ref>
<ref id="bibr35-0300060513476436"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer</article-title>. <source>Cancer Sci</source> <year>2011</year>; <volume>102</volume>: <fpage>2029</fpage>–<lpage>2037</lpage>.</citation></ref>
<ref id="bibr36-0300060513476436"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tomizawa</surname><given-names>Y</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Kondo</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene <italic>SEMA3B</italic></article-title>. <source>Proc Natl Acad Sci USA</source> <year>2001</year>; <volume>98</volume>: <fpage>13954</fpage>–<lpage>13959</lpage>.</citation></ref>
<ref id="bibr37-0300060513476436"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Geiger</surname><given-names>TR</given-names></name><name><surname>Peeper</surname><given-names>DS</given-names></name></person-group>. <article-title>Metastasis mechanisms</article-title>. <source>Biochim Biophys Acta</source> <year>2009</year>; <volume>1796</volume>: <fpage>293</fpage>–<lpage>308</lpage>.</citation></ref>
</ref-list>
</back>
</article>